{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:20:21Z","timestamp":1791829221448,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40263-026-01292-x","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T02:11:12Z","timestamp":1775441472000},"page":"737-741","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Is Crisugabalin Signaling the Arrival of a Third Generation of \u03b12\u03b4 Ligands?"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5994-2970","authenticated-orcid":false,"given":"Antonio","family":"Alc\u00e1ntara Montero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"1292_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S1474-4422(25)00068-7","volume":"24","author":"N Soliman","year":"2025","unstructured":"Soliman N, Moisset X, Ferraro MC, et al. Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. Lancet Neurol. 2025;24:413\u201328. https:\/\/doi.org\/10.1016\/S1474-4422(25)00068-7.","journal-title":"Lancet Neurol"},{"key":"1292_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162\u201373. https:\/\/doi.org\/10.1016\/S1474-4422(14)70251-0.","journal-title":"Lancet Neurol"},{"key":"1292_CR3","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/j.1468-1331.2010.02999.x","volume":"17","author":"N Attal","year":"2010","unstructured":"Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113-e88. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.02999.x.","journal-title":"Eur J Neurol"},{"key":"1292_CR4","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","volume":"397","author":"SP Cohen","year":"2021","unstructured":"Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances. Lancet. 2021;397:2082\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(21)00393-7.","journal-title":"Lancet"},{"key":"1292_CR5","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S1474-4422(10)70143-5","volume":"9","author":"R Baron","year":"2010","unstructured":"Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9:807\u201319. https:\/\/doi.org\/10.1016\/S1474-4422(10)70143-5.","journal-title":"Lancet Neurol"},{"key":"1292_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007076.pub3","volume":"1","author":"S Derry","year":"2019","unstructured":"Derry S, Bell RF, Straube S, et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;1:CD007076. https:\/\/doi.org\/10.1002\/14651858.CD007076.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"1292_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.31647","volume":"3","author":"K Bykov","year":"2020","unstructured":"Bykov K, Bateman BT, Franklin JM, et al. Association of gabapentinoids with the risk of opioid-related adverse events in surgical patients in the United States. JAMA Netw Open. 2020;3:e2031647. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.31647.","journal-title":"JAMA Netw Open"},{"key":"1292_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40265-017-0700-x","volume":"77","author":"KE Evoy","year":"2017","unstructured":"Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77:403\u201326. https:\/\/doi.org\/10.1007\/s40265-017-0700-x.","journal-title":"Drugs"},{"key":"1292_CR9","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/add.13324","volume":"111","author":"RV Smith","year":"2016","unstructured":"Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016;111:1160\u201374. https:\/\/doi.org\/10.1111\/add.13324.","journal-title":"Addiction"},{"key":"1292_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000355268","volume":"20","author":"CR Baird","year":"2014","unstructured":"Baird CR, Fox P, Colvin LA. Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers. Eur Addict Res. 2014;20:115\u20138. https:\/\/doi.org\/10.1159\/000355268.","journal-title":"Eur Addict Res"},{"key":"1292_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2021.110830","volume":"324","author":"P Kriikku","year":"2021","unstructured":"Kriikku P, Ojanper\u00e4 I. Pregabalin and gabapentin in non-opioid poisoning deaths. Forensic Sci Int. 2021;324:110830. https:\/\/doi.org\/10.1016\/j.forsciint.2021.110830.","journal-title":"Forensic Sci Int"},{"key":"1292_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002396","volume":"14","author":"T Gomes","year":"2017","unstructured":"Gomes T, Juurlink DN, Antoniou T, et al. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLoS Med. 2017;14:e1002396. https:\/\/doi.org\/10.1371\/journal.pmed.1002396.","journal-title":"PLoS Med"},{"key":"1292_CR13","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.1074\/jbc.271.10.5768","volume":"271","author":"NS Gee","year":"1996","unstructured":"Gee NS, Brown JP, Dissanayake VU, et al. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem. 1996;271:5768\u201376. https:\/\/doi.org\/10.1074\/jbc.271.10.5768.","journal-title":"J Biol Chem"},{"key":"1292_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.eplepsyres.2006.09.008","volume":"73","author":"CP Taylor","year":"2007","unstructured":"Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73:137\u201350. https:\/\/doi.org\/10.1016\/j.eplepsyres.2006.09.008.","journal-title":"Epilepsy Res"},{"key":"1292_CR15","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/11536200-000000000-00000","volume":"49","author":"HN Bockbrader","year":"2010","unstructured":"Bockbrader HN, Wesche D, Miller R, et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49:661\u20139. https:\/\/doi.org\/10.2165\/11536200-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"key":"1292_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007938.pub3","volume":"2014","author":"RA Moore","year":"2014","unstructured":"Moore RA, Wiffen PJ, Derry S, et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;2014:CD007938. https:\/\/doi.org\/10.1002\/14651858.CD007938.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"1292_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002369","volume":"14","author":"H Shanthanna","year":"2017","unstructured":"Shanthanna H, Gilron I, Rajarathinam M, et al. Benefits and safety of gabapentinoids in chronic low back pain: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2017;14:e1002369. https:\/\/doi.org\/10.1371\/journal.pmed.1002369.","journal-title":"PLoS Med"},{"key":"1292_CR18","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1124\/jpet.117.247551","volume":"365","author":"Y Domon","year":"2018","unstructured":"Domon Y, Arakawa N, Inoue T, et al. Characteristics and analgesic effects of mirogabalin, a novel ligand for the \u03b12\u03b4 subunit of voltage-gated calcium channels. J Pharmacol Exp Ther. 2018;365:573\u201382. https:\/\/doi.org\/10.1124\/jpet.117.247551.","journal-title":"J Pharmacol Exp Ther"},{"key":"1292_CR19","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/jdi.13013","volume":"10","author":"M Baba","year":"2019","unstructured":"Baba M, Matsui N, Kuroha M, et al. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase III study in Asian patients. J Diabetes Investig. 2019;10:1299\u2013306. https:\/\/doi.org\/10.1111\/jdi.13013.","journal-title":"J Diabetes Investig."},{"key":"1292_CR20","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s40122-024-00617-2","volume":"13","author":"X Guo","year":"2024","unstructured":"Guo X, Yu Y, Zhang Y, et al. A phase 3, multicenter, randomized, double-blind, placebo-controlled 14-week study of mirogabalin in Chinese patients with diabetic peripheral neuropathic pain. Pain Ther. 2024;13:937\u201352. https:\/\/doi.org\/10.1007\/s40122-024-00617-2.","journal-title":"Pain Ther"},{"key":"1292_CR21","doi-asserted-by":"publisher","first-page":"1491570","DOI":"10.3389\/fphar.2024.1491570","volume":"15","author":"F Yang","year":"2024","unstructured":"Yang F, Wang Y, Zhang M, et al. Mirogabalin as a novel calcium channel \u03b12\u03b4 ligand for the treatment of neuropathic pain: a review of clinical update. Front Pharmacol. 2024;15:1491570. https:\/\/doi.org\/10.3389\/fphar.2024.1491570.","journal-title":"Front Pharmacol"},{"key":"1292_CR22","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1080\/03007995.2019.1629757","volume":"35","author":"LM Arnold","year":"2019","unstructured":"Arnold LM, Whitaker S, Hsu C, et al. Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study. Curr Med Res Opin. 2019;35:1825\u201335. https:\/\/doi.org\/10.1080\/03007995.2019.1629757.","journal-title":"Curr Med Res Opin"},{"key":"1292_CR23","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1021\/acs.jcim.5c02583","volume":"66","author":"Z Chen","year":"2026","unstructured":"Chen Z, Gou X, Meng Q, et al. Structural and computational insights into the mechanism of the superior pharmacological activity of crisugabalin: a third-generation Cav\u03b12\u03b41 ligand. J Chem Inf Model. 2026;66:632\u201341. https:\/\/doi.org\/10.1021\/acs.jcim.5c02583.","journal-title":"J Chem Inf Model"},{"key":"1292_CR24","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1124\/jpet.120.000315","volume":"376","author":"X Gou","year":"2021","unstructured":"Gou X, Yu X, Bai D, et al. Pharmacology and mechanism of action of HSK16149, a selective ligand of \u03b1 2 \u03b4 subunit of voltage-gated calcium channel with analgesic activity in animal models of chronic pain. J Pharmacol Exp Ther. 2021;376:330\u20137. https:\/\/doi.org\/10.1124\/jpet.120.000315.","journal-title":"J Pharmacol Exp Ther"},{"key":"1292_CR25","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s40122-025-00771-1","volume":"14","author":"Y Wu","year":"2025","unstructured":"Wu Y, Guo X, Zhang J. Calcium channel \u03b12\u03b4 ligands mirogabalin, pregabalin, and gabapentin: advancements in diabetic peripheral neuropathic pain therapeutics. Pain Ther. 2025;14:1647\u201386. https:\/\/doi.org\/10.1007\/s40122-025-00771-1.","journal-title":"Pain Ther"},{"key":"1292_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2025.174015","volume":"252","author":"X Gou","year":"2025","unstructured":"Gou X, Liu Y, Ye Q, et al. Crisugabalin, a ligand for the \u03b12\u03b4 subunit of voltage-gated calcium channels, exhibits no obvious abuse potential in rodents. Pharmacol Biochem Behav. 2025;252:174015. https:\/\/doi.org\/10.1016\/j.pbb.2025.174015.","journal-title":"Pharmacol Biochem Behav"},{"key":"1292_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.25614","volume":"7","author":"X Guo","year":"2024","unstructured":"Guo X, Zhang T, Yuan G, et al. GABA analogue HSK16149 in Chinese patients with diabetic peripheral neuropathic pain: a phase 3 randomized clinical trial. JAMA Netw Open. 2024;7:e2425614. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.25614.","journal-title":"JAMA Netw Open"},{"key":"1292_CR28","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s40122-025-00745-3","volume":"14","author":"T Pan","year":"2025","unstructured":"Pan T, Ma J, Li Y, et al. Rapid onset of pain relief with crisugabalin in patients with diabetic peripheral neuropathic pain: findings from a multicenter, randomized, double-blind, controlled study. Pain Ther. 2025;14:1311\u201329. https:\/\/doi.org\/10.1007\/s40122-025-00745-3.","journal-title":"Pain Ther"},{"key":"1292_CR29","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1001\/jamadermatol.2024.3410","volume":"160","author":"D Zhang","year":"2024","unstructured":"Zhang D, Lei T, Qin L, et al. Efficacy and safety of crisugabalin (HSK16149) in adults with postherpetic neuralgia: a phase 3 randomized clinical trial. JAMA Dermatol. 2024;160:1182\u201391. https:\/\/doi.org\/10.1001\/jamadermatol.2024.3410.","journal-title":"JAMA Dermatol"},{"key":"1292_CR30","doi-asserted-by":"publisher","DOI":"10.1155\/jdr\/2960736","volume":"2026","author":"X Guo","year":"2026","unstructured":"Guo X, Wang K, Zhang T, et al. Long-term safety and efficacy of crisugabalin for diabetic peripheral neuropathic pain: a 52-week, multicenter, single-arm trial. J Diabetes Res. 2026;2026:e2960736. https:\/\/doi.org\/10.1155\/jdr\/2960736.","journal-title":"J Diabetes Res"},{"key":"1292_CR31","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/bcp.70310","volume":"92","author":"S Lin","year":"2026","unstructured":"Lin S, Wang Y, Hu C, et al. Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment. Br J Clin Pharmacol. 2026;92:903\u201310. https:\/\/doi.org\/10.1002\/bcp.70310.","journal-title":"Br J Clin Pharmacol"},{"key":"1292_CR32","unstructured":"ClinicalTrials.gov. Search results for: crisugabalin. 2026. Available from: https:\/\/clinicaltrials.gov\/search?intr=Crisugabalin. Accessed 27 Jan 2026."},{"key":"1292_CR33","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S580694","volume":"19","author":"M Liu","year":"2026","unstructured":"Liu M, Li R, Zhou H, et al. The efficacy and safety of crisugabalin (HSK16149) in fibromyalgia patients: protocol for a prospective randomized open blinded-endpoint (PROBE) study. J Pain Res. 2026;19:580694. https:\/\/doi.org\/10.2147\/JPR.S580694.","journal-title":"J Pain Res"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01292-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01292-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01292-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:38:23Z","timestamp":1779802703000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01292-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1292"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01292-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Antonio Alc\u00e1ntara Montero has no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No datasets were generated or analyzed during the current commentary.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Antonio Alc\u00e1ntara Montero conceived the study, collected and analyzed the data, and wrote the manuscript. The author reviewed and approved the final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}